GENOMICS AND PROTEOMICS REAGENTS, RESEARCH KITS, & ANALYTICAL INSTRUMENTATION MARKET ANALYSIS

Genomics and Proteomics Reagents, Research Kits, & Analytical Instrumentation Market, By Product Type (Instrumentation and Analytical Tools (Chromatography, Mass Spectrometry, Thermal Cyclers, Next Gen Sequencing), Reagents and Research Kits (Sample Prep Kits, Electrophoresis Kits, Purification Kits, BioChips)), By End User (Diagnostic Laboratories, Pharmaceutical and Biotechnology Organizations, Research Laboratories), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East & Africa) - Size, Share, Outlook, and Opportunity Analysis, 2020 - 2027

Published In : Aug 2020
Code : CMI4109
Pages :176
Formats :
Excel and PDF
Industry : Biotechnology

Market Challenges And Opportunities

Global Genomics and Proteomics Reagents, Research Kits, and Analytical Instrumentation Market: Restraints

Low adoption and penetration of reagents, research kits, and analytical instrumentation in developing countries is expected to hinder growth of the market. This can be attributed to the high cost of the equipment and high capital investment required to set up a modern laboratory.

Moreover, the market is highly fragmented, which increases volume but reduced revenue of the market. This in turn is expected to hinder growth of the market.

Global Genomics and Proteomics Reagents, Research Kits, and Analytical Instrumentation Market: Opportunities

Increasing prevalence of chronic disorders is expected to offer lucrative growth opportunities for players in the global genomics and proteomics reagents, research kits, and analytical instrumentation market. For instance, according to the American Cancer Society, in 2019, there will be an estimated 1,762,450 new cancer cases diagnosed and 606,880 cancer deaths in the U.S.

Moreover, increasing adoption of proteomics in disease diagnostics is also expected to aid in growth of the market. For instance, in September 2019, researchers from Eulji University, South Korea, reported use of proteomics approach to identify two proteins, namely serum amyloid A4 and vitamin D binding protein that demonstrated high performance in distinguishing patients with rheumatoid arthritis from healthy controls.